Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15866138 | 1.00 | PTPN1 (0.45) | PTPN1FUCA1ACHEDRD2RECQL | |
| SCHEMBL5745374 | 1.00 | PTPN1 (0.45) | PTPN1FUCA1ACHEDRD2RECQL | |
| SCHEMBL13379049 | 0.91 | PTPN1 (0.48) | PTPN1FUCA1ACHEDRD2RECQL | |
| SCHEMBL10522832 | 0.91 | PTPN1 (0.48) | PTPN1FUCA1ACHEDRD2RECQL | |
| SCHEMBL3833437 | 0.91 | PTPN1 (0.48) | PTPN1FUCA1ACHEDRD2RECQL | |
| SCHEMBL5745124 | 0.88 | ACHE (0.50) | ACHEDRD2RECQLSMN1; SMN2CYP2D6 | |
| SCHEMBL5744578 | 0.88 | ACHE (0.50) | ACHEDRD2RECQLSMN1; SMN2CYP2D6 | |
| SCHEMBL12347368 | 0.85 | PTPN1 (0.42) | PTPN1FUCA1ACHEDRD2RECQL | |
| SCHEMBL18453426 | 0.84 | PTPN1 (0.44) | PTPN1FUCA1ACHEDRD2RECQL | |
| SCHEMBL4440958 | 0.84 | PTPN1 (0.44) | PTPN1FUCA1DRD2RECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | ZHANGZHOU PIEN TZE HUANG PHARMACEUTICAL CO., LTD. (CN) | 2023-07-25 | — | — | US | disclosed |
| EP-0443498-A1 | Isoindoline derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1991-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708357-B2 | Crystal form of pyrrolidinyl urea derivative and application thereof | NGF, LCK, RET | PTPN1 472/4885FUCA1 3455/4885ACHE 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.